Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Amgen

439.33
+8.121.88%
Post-market: 439.05-0.2800-0.06%19:56 EDT
Volume:2.11M
Turnover:926.13M
Market Cap:236.57B
PE:27.29
High:440.51
Open:431.72
Low:429.38
Close:431.21
52wk High:443.20
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.82
T/O Rate:0.39%
Dividend:9.80
Dividend Rate:2.23%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:20.24
PE(LYR):30.87

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Amgen
Exchange:
NASDAQ
Establishment Date:
1980
Employees:
31500
Office Location:
One Amgen Center Drive,Thousand Oaks,California,United States
Website:
http://www.amgen.com
Zip Code:
91320-1799
Phone:
805 447 1000
Fax:
805 447 1010
Introduction:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Directors

Name
Position
Robert A. Bradway
Chairman of the Board and Director and President and Chief Executive Officer
Amy E. Miles
Independent Director
Brian J. Druker
Independent Director
Charles M. Holley, Jr.
Independent Director
Ellen J. Kullman
Independent Director
Gregory C. Garland
Independent Director
Mary E. Klotman
Independent Director
Michael V. Drake
Independent Director
Robert A. Eckert
Lead Independent Director
S. Omar Ishrak
Independent Director
Tyler E. Jacks
Independent Director
Wanda M. Austin
Independent Director

Shareholders

Name
Position
Robert A. Bradway
Chairman of the Board and Director and President and Chief Executive Officer
Derek Miller
Senior Vice President, Human Resources
Nancy A. Grygiel
Chief Compliance Officer and Senior Vice President
Rachna Khosla
Senior Vice President, Business Development
Thomas Dittrich
Executive Vice President and Chief Financial Officer
Esteban Santos
Executive Vice President, Operations
James E. Bradner
Executive Vice President, Research and Development
Jonathan P. Graham
Executive Vice President and General Counsel and Secretary
Matthew C. Busch
Vice President, Finance and Chief Accounting Officer
Murdo Gordon
Executive Vice President, Global Commercial Operations